Abstract
Background The first case of SARS-CoV-2 in Basel, Switzerland was detected on February 26th 2020. We present a phylogenetic study to explore viral introduction and evolution during the exponential early phase of the local COVID-19 outbreak from February 26th until March 23rd.
Methods We sequenced SARS-CoV-2 naso-oropharyngeal swabs from positive 746 tests that were performed at the University Hospital Basel in the timeframe of our study. We successfully generated 468 high quality genomes from unique patients and called variants with our COVID-19 Pipeline (COVGAP). We analysed viral genetic diversity using PANGOLIN taxonomic lineages. To identify introduction and dissemination events we incorporated global SARS-CoV-2 genomes and inferred a time-calibrated phylogeny. We used epidemiological data to aid interpretation of phylogenetic patterns.
Findings The early outbreak in Basel was dominated by lineage B.1 (83·6%), detected from March 2nd, although the first lineage identified was B.1.1. Within B.1, a clade defined by the SNP C15324T contains 68·2% of our samples (‘Basel cluster’), including 157 identical sequences at the root of the ‘Basel cluster’, suggesting local spreading events. We infer the origin of the ‘Basel cluster’ defining mutation to mid-February in our tri-national region. The remaining genomes map broadly over the global phylogenetic tree, evidencing several events of introduction from and/or dissemination to other regions of the world via travellers. We also observe family transmission events.
Interpretation A single lineage variant dominated the outbreak in the City of Basel while other lineages such as the first (B1.1) did not propagate. We identify mass gathering events and less so travel returners and family transmission as causes for the local outbreak. We highlight the importance of adding specific questions to the epidemiological questionnaires that are collected, to obtain data on attendance of large gathering events and locations as well as travel history to effectively identify routes of transmissions in up-coming outbreaks. This phylogenetic analysis enriches epidemiological and contact tracing data, allowing, even retrospectively, connection of seemingly unconnected events, and can inform public health interventions.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04351503
Funding Statement
No dedicated funding was used for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to good laboratory practice and in accordance with the Declaration of Helsinki and national and institutional standards and was approved by the ethical committee (EKNZ 2020-00769).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Reference added and acknowledgement amended
Data Availability
Sequencing data (viral reads only) was submitted to European Nucleotide Archive (ENA) under accession number PRJEB39887, consensus sequences were submitted to GISAID, bioinformatic pipelines are accessible on Github.
